Plexxikon

Cancer drugmaker Plexxikon gets new life as Opna Bio
Cancer drugmaker Plexxikon gets new life as Opna Bio
BioPharma Dive
Plexxikon
Opna Bio
rebranding
oncology
Daiichi Sankyo
Flag link:
Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development
Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development
Endpoints
Daiichi Sankyo
Plexxikon
Enhertu
Flag link:
Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty
Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty
Endpoints
Novartis
patents
Tafinlar
Plexxikon
Daiichi Sankyo
Flag link:
Biotech Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon
Biotech Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon
Fierce Biotech
Novellus
Plexxikon
BRAF inhibitor
PLX8394
Flag link:
Roche's vemurafenib plays a starring role at ASCO
Roche's vemurafenib plays a starring role at ASCO
Fierce Biotech
Roche
ASCO
vemurafenib
Plexxikon
melanoma
Flag link:
Roche cancer programs angle for a starring role at ASCO
Roche cancer programs angle for a starring role at ASCO
Fierce Biotech
Roche
ASCO
skin cancer
Plexxikon
Flag link:
10 promising late-stage cancer drugs
10 promising late-stage cancer drugs
Fierce Biotech
cancer
Carfilzomib
crizotinib
vismodegib
Oncovex
PLX4032
Ponatinib
SGN-35
tivozanib
T-DM1
cabozantinib
ONYX Pharmaceuticals
Pfizer
Genentech
Curis
Amgen
Plexxikon
Seattle Genetics
Ariad Pharmaceuticals
Aveo Pharmaceutical
Exelixis
Roche
Flag link:
Daiichi Sankyo, Kyowa Hakko Signal More Japanese Drug Takeovers
Daiichi Sankyo, Kyowa Hakko Signal More Japanese Drug Takeovers
Bloomberg
Japan
Kyowa Hakko Kirin
Daiichi Sankyo
Plexxikon
Prostrakan
M&A
Flag link:
Daiichi Sankyo nabs tiny Plexxikon in $935M deal
Daiichi Sankyo nabs tiny Plexxikon in $935M deal
Fierce Biotech
Plexxikon
Daiichi Sankyo
M&A
Flag link:
Roche Scores Big With Plexxikon and Immunogen Deals
Roche Scores Big With Plexxikon and Immunogen Deals
Seeking Alpha
Roche
Immunogen
Plexxikon
personalized medicine
Flag link:
Four Big Areas to Watch at the Upcoming ASCO Meeting, Biotech's Biggest Cancer Confab
Four Big Areas to Watch at the Upcoming ASCO Meeting, Biotech's Biggest Cancer Confab
BNET Pharma
Avastin
Nektar
Sunesis
ASCO
cancer
vaccines
personalized medicine
ovarian cancer
Celgene
Revlimid
Rituxan
Roche
Dendreon
Provenge
Celldex
Pfizer
Argos
Plexxikon
Flag link:
Plexxikon Treats Initial Patient with First-in-Class Drug in Phase 1 Trial
Plexxikon Treats Initial Patient with First-in-Class Drug in Phase 1 Trial
Pipeline Review
Plexxikon
cancer
rheumatoid arthritis
Flag link: